{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:40:58Z","timestamp":1790887258945,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1097\/01.mlr.0000233679.20898.e9","type":"journal-article","created":{"date-parts":[[2006,9,18]],"date-time":"2006-09-18T04:10:35Z","timestamp":1158552635000},"page":"893-899","source":"Crossref","is-referenced-by-count":34,"title":["Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients With Human Immunodeficiency Virus"],"prefix":"10.1097","volume":"44","author":[{"given":"Julie","family":"Munakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Dezii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth H.","family":"Hazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonothan C.","family":"Tierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210211","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.280.17.1497","article-title":"Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.","volume":"280","author":"Detels","year":"1998","journal-title":"JAMA"},{"key":"R2-2-20210211","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"R3-2-20210211","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.","volume":"341","author":"Staszewski","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-2-20210211","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJM200103153441108","article-title":"The cost effectiveness of combination antiretroviral therapy for HIV disease.","volume":"344","author":"Freedberg","year":"2001","journal-title":"N Engl J Med"},{"key":"R5-2-20210211","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1468-1293.2001.00048.x","article-title":"Assessing the cost-effectiveness of HAART for adults with HIV in England.","volume":"2","author":"Miners","year":"2001","journal-title":"HIV Med"},{"key":"R6-2-20210211","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1056\/NEJM199312303292710","article-title":"Evaluating drugs after their approval for clinical use.","volume":"329","author":"Ray","year":"1993","journal-title":"N Engl J Med"},{"key":"R7-2-20210211","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00042560-200203010-00004","article-title":"Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.","volume":"29","author":"Fumaz","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-2-20210211","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","article-title":"Variations in patients\u2019 adherence to medical recommendations: a quantitative review of 50 years of research.","volume":"42","author":"DiMatteo","year":"2004","journal-title":"Med Care"},{"key":"R10-2-20210211","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00002030-200003100-00008","article-title":"Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.","volume":"14","author":"Bangsberg","year":"2000","journal-title":"AIDS"},{"key":"R11-2-20210211","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00042560-199806010-00003","article-title":"Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.","volume":"18","author":"Eldred","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R12-2-20210211","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/00002030-199906180-00014","article-title":"The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.","volume":"13","author":"Haubrich","year":"1999","journal-title":"AIDS"},{"key":"R13-2-20210211","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00126334-200004010-00016","article-title":"Adherence to triple therapy and viral load response.","volume":"23","author":"Low-Beer","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-2-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"R15-2-20210211","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","article-title":"Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.","volume":"15","author":"Bangsberg","year":"2001","journal-title":"AIDS"},{"key":"R16-2-20210211","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00002030-200205030-00012","article-title":"Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.","volume":"16","author":"Hogg","year":"2002","journal-title":"AIDS"},{"issue":"Suppl 1","key":"R17-2-20210211","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00126334-200202011-00002","article-title":"Addressing the challenges of adherence.","volume":"29","author":"Bartlett","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-2-20210211","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/09540120500100635","article-title":"The cost of HIV medication adherence support interventions: results of a cross-site evaluation.","volume":"17","author":"Schackman","year":"2005","journal-title":"AIDS Care"},{"key":"R19-2-20210211","article-title":"Cost-Effectiveness in Health and Medicine.","year":"1996"},{"key":"R20-2-20210211","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/135965350300800606","article-title":"Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study.","volume":"8","author":"Carrieri","year":"2003","journal-title":"Antivir Ther"},{"key":"R21-2-20210211","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMsa042657","article-title":"Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.","volume":"352","author":"Sanders","year":"2005","journal-title":"N Engl J Med"},{"key":"R22-2-20210211","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"R23-2-20210211","article-title":"Two-year analysis of stavudine extended-release\/prolonged release capsules (xr\/prc) as compared to stavudine immediate-release (ir): efficacy and safety.","author":"Brett-Smith","year":"2003"},{"key":"R24-2-20210211","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1086\/339074","article-title":"The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.","volume":"34","author":"Mannheimer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R25-2-20210211","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/archinte.161.16.1962","article-title":"Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.","volume":"161","author":"Nieuwkerk","year":"2001","journal-title":"Arch Intern Med"},{"key":"R26-2-20210211","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.","volume":"14","author":"Baxter","year":"2000","journal-title":"AIDS"},{"key":"R27-2-20210211","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00126334-200209010-00004","article-title":"Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.","volume":"31","author":"Walensky","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R28-2-20210211","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1468-1293.2002.00109.x","article-title":"Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy.","volume":"3","author":"Raboud","year":"2002","journal-title":"HIV Med"},{"key":"R29-2-20210211","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"R30-2-20210211","article-title":"National Center for Health Statistics. Vital Statistics of the United States, 1995: Preprint of Volume II, Mortality, Part A, Section 6: life tables. DHHS Publication no. (PHS) 98-1147.","year":"1998"},{"key":"R31-2-20210211","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJM200103153441107","article-title":"Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.","volume":"344","author":"Bozzette","year":"2001","journal-title":"N Engl J Med"},{"key":"R32-2-20210211","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/135965350200700405","article-title":"Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.","volume":"7","author":"Yazdanpanah","year":"2002","journal-title":"Antivir Ther"},{"key":"R33-2-20210211","article-title":"Incremental costs of HIV suppression in HIV therapeutic failure.","author":"Stansell","year":"2000"},{"key":"R34-2-20210211","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00115677-200210020-00003","article-title":"Clinical and economic implications of non-adherence to HAART in HIV infection.","volume":"10","author":"Scalera","year":"2002","journal-title":"Disease Management Health Outcomes"},{"key":"R35-2-20210211","article-title":"Drug Topics Red Book.","year":"2002"},{"key":"R36-2-20210211","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1008969512182","article-title":"Economic methods for measuring the quality of life associated with HIV infection.","volume":"8","author":"Bayoumi","year":"1999","journal-title":"Qual Life Res"},{"key":"R37-2-20210211","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00042560-199709010-00009","article-title":"Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.","volume":"16","author":"Holtgrave","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R38-2-20210211","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00005650-199601000-00004","article-title":"Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning.","volume":"34","author":"Tsevat","year":"1996","journal-title":"Med Care"},{"key":"R39-2-20210211","doi-asserted-by":"crossref","first-page":"440","DOI":"10.7326\/0003-4819-134-6-200103200-00008","article-title":"Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.","volume":"134","author":"Weinstein","year":"2001","journal-title":"Ann Intern Med"},{"key":"R40-2-20210211","first-page":"185","article-title":"Antiretroviral adherence interventions: a review of current literature and ongoing studies.","volume":"11","author":"Simoni","year":"2003","journal-title":"Top HIV Med"},{"key":"R41-2-20210211","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00126334-200011010-00003","article-title":"Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.","volume":"25","author":"Tuldra","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-2-20210211","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1046\/j.1525-1497.2000.00127.x","article-title":"Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention.","volume":"15","author":"Rigsby","year":"2000","journal-title":"J Gen Intern Med"},{"key":"R43-2-20210211","first-page":"78","article-title":"[Adherence to very active antiretroviral treatment: impact of individualized assessment].","volume":"17","author":"Knobel","year":"1999","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R44-2-20210211","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjmed.2003.07.007","article-title":"Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.","volume":"115","author":"Goldie","year":"2003","journal-title":"Am J Med"},{"key":"R45-2-20210211","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jama.283.2.250","article-title":"Resistance, fitness, adherence, and potency: mapping the paths to virologic failure.","volume":"283","author":"Markowitz","year":"2000","journal-title":"JAMA"},{"key":"R46-2-20210211","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/426595","article-title":"Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.","volume":"40","author":"Maggiolo","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R47-2-20210211","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2648.2003.02928.x","article-title":"Successful adherence after multiple HIV treatment failures.","volume":"45","author":"Enriquez","year":"2004","journal-title":"J Adv Nurs"},{"issue":"Suppl 3","key":"R49-2-20210211","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1097\/00126334-200212153-00005","article-title":"Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.","volume":"31","author":"Press","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R50-2-20210211","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/108729101753145484","article-title":"Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units.","volume":"15","author":"Brook","year":"2001","journal-title":"AIDS Patient Care STDS"}],"container-title":["Medical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mlr.0000233679.20898.e9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:20:05Z","timestamp":1785860405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005650-200610000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mlr.0000233679.20898.e9","relation":{},"ISSN":["0025-7079"],"issn-type":[{"value":"0025-7079","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}